

Sobha Sivaprasad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1893575/publications.pdf>

Version: 2024-02-01

380
papers

13,426
citations

25034

57
h-index

33894

99
g-index

399
all docs

399
docs citations

399
times ranked

12007
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 2211.	7.4	1,442
2	Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology, 2015, 99, 220-226.	3.9	474
3	Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. Circulation Research, 2013, 112, 595-600.	4.5	366
4	Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide Perspective. Survey of Ophthalmology, 2012, 57, 347-370.	4.0	299
5	Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet, The, 2017, 389, 2193-2203.	13.7	279
6	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research, 2019, 73, 100770.	15.5	276
7	Defining response to anti-VEGF therapies in neovascular AMD. Eye, 2015, 29, 721-731.	2.1	214
8	Automated segmentation of exudates, haemorrhages, microaneurysms using single convolutional neural network. Information Sciences, 2017, 420, 66-76.	6.9	210
9	Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabetic Medicine, 2013, 30, 640-650.	2.3	209
10	Artificial intelligence using deep learning to screen for referable and vision-threatening diabetic retinopathy in Africa: a clinical validation study. The Lancet Digital Health, 2019, 1, e35-e44.	12.3	205
11	IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Research and Clinical Practice, 2019, 157, 107840.	2.8	202
12	Segmentation of optic disc, fovea and retinal vasculature using a single convolutional neural network. Journal of Computational Science, 2017, 20, 70-79.	2.9	196
13	Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nature Genetics, 2020, 52, 160-166.	21.4	192
14	Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. British Journal of Ophthalmology, 2009, 93, 1341-1344.	3.9	163
15	Hypoxia and Oxidative Stress in the Causation of Diabetic Retinopathy. Current Diabetes Reviews, 2011, 7, 291-304.	1.3	160
16	Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 2019, 242, 123-162.	1.9	153
17	Diagnostic Accuracy of Community-Based Diabetic Retinopathy Screening With an Offline Artificial Intelligence System on a Smartphone. JAMA Ophthalmology, 2019, 137, 1182.	2.5	146
18	Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 294-303.	13.7	134

#	ARTICLE	IF	CITATIONS
19	Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. <i>Progress in Retinal and Eye Research</i> , 2022, 86, 100973.	15.5	133
20	Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. <i>Progress in Retinal and Eye Research</i> , 2020, 79, 100865.	15.5	125
21	Sickle Cell Disease and the Eye: Old and New Concepts. <i>Survey of Ophthalmology</i> , 2010, 55, 359-377.	4.0	119
22	Ethnic Variations in the Prevalence of Diabetic Retinopathy in People with Diabetes Attending Screening in the United Kingdom (DRIVE UK). <i>PLoS ONE</i> , 2012, 7, e32182.	2.5	113
23	Age-related Macular Degeneration detection using deep convolutional neural network. <i>Future Generation Computer Systems</i> , 2018, 87, 127-135.	7.5	109
24	Fundus photograph-based deep learning algorithms in detecting diabetic retinopathy. <i>Eye</i> , 2019, 33, 97-109.	2.1	109
25	Micropulsed Diode Laser Therapy: Evolution and Clinical Applications. <i>Survey of Ophthalmology</i> , 2010, 55, 516-530.	4.0	108
26	Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. <i>British Journal of Ophthalmology</i> , 2016, 100, 1623-1628.	3.9	104
27	Ranibizumab in Myopic Choroidal Neovascularization: The 12-Month Results from the REPAIR Study. <i>Ophthalmology</i> , 2013, 120, 1944-1945.e1.	5.2	94
28	Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. <i>Health Technology Assessment</i> , 2015, 19, 1-116.	2.8	90
29	Treatment of proliferative diabetic retinopathy with anti-VEGF agents. <i>Acta Ophthalmologica</i> , 2011, 89, 405-411.	1.1	89
30	Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. <i>Translational Vision Science and Technology</i> , 2016, 5, 2.	2.2	89
31	First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 337-343.	5.2	85
32	Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). <i>Ophthalmology</i> , 2018, 125, 691-700.	5.2	84
33	Estimation of Systemic Complement C3 Activity in Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2007, 125, 515.	2.4	82
34	Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion. <i>JAMA Ophthalmology</i> , 2019, 137, 1256.	2.5	80
35	Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. <i>Eye</i> , 2007, 21, 1511-1515.	2.1	79
36	Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 640-644.	2.6	76

#	ARTICLE	IF	CITATIONS
37	Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. <i>Clinical Ophthalmology</i> , 2016, 10, 939.	1.8	76
38	Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: The DRIVE UK Study. <i>Eye</i> , 2012, 26, 510-516.	2.1	75
39	A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (the LUCIDATE Study). <i>American Journal of Ophthalmology</i> , 2014, 157, 960-970.e2.	3.3	75
40	Myopic foveoschisis: a clinical review. <i>Eye</i> , 2015, 29, 593-601.	2.1	75
41	Photodynamic therapy for central serous chorioretinopathy. <i>Eye</i> , 2014, 28, 944-957.	2.1	74
42	Spectral domain optical coherence tomography in patients with sickle cell disease. <i>British Journal of Ophthalmology</i> , 2015, 99, 967-972.	3.9	74
43	Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting. <i>American Journal of Ophthalmology</i> , 2016, 172, 51-57.	3.3	74
44	HYPERREFLECTIVE FOCI AS AN INDEPENDENT VISUAL OUTCOME PREDICTOR IN MACULAR EDEMA DUE TO RETINAL VASCULAR DISEASES TREATED WITH INTRAVITREAL DEXAMETHASONE OR RANIBIZUMAB. <i>Retina</i> , 2016, 36, 2319-2328.	1.7	73
45	Deep Learning for Prediction of AMD Progression: A Pilot Study. , 2019, 60, 712.		73
46	Diagnostic accuracy of disorganization of the retinal inner layers in detecting macular capillary non-perfusion in diabetic retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2015, 43, 735-741.	2.6	72
47	Perspectives on reticular pseudodrusen in age-related macular degeneration. <i>Survey of Ophthalmology</i> , 2016, 61, 521-537.	4.0	72
48	An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification. <i>European Journal of Ophthalmology</i> , 2020, 30, 8-18.	1.3	70
49	The pathogenesis of early retinal changes of diabetic retinopathy. <i>Documenta Ophthalmologica</i> , 2012, 124, 15-26.	2.2	69
50	Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. <i>British Journal of Ophthalmology</i> , 2005, 89, 1420-1422.	3.9	66
51	Age, Sex, and Ethnic Variations in Inner and Outer Retinal and Choroidal Thickness on Spectral-Domain Optical Coherence Tomography. <i>American Journal of Ophthalmology</i> , 2015, 160, 1034-1043.e1.	3.3	66
52	Intravitreal steroids in the management of macular oedema. <i>Acta Ophthalmologica</i> , 2006, 84, 722-733.	0.3	64
53	Socio-economic and ethnic inequalities in diabetes retinal screening. <i>Diabetic Medicine</i> , 2010, 27, 282-288.	2.3	64
54	Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. <i>Ophthalmology Retina</i> , 2020, 4, 1043-1046.	2.4	64

#	ARTICLE	IF	CITATIONS
55	The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D). <i>Diabetologia</i> , 2013, 56, 1272-1281.	6.3	61
56	The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. <i>Eye</i> , 2015, 29, 1633-1638.	2.1	61
57	Altered circulating mitochondrial DNA and increased inflammation in patients with diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 257-265.	2.8	61
58	Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. <i>Clinical Ophthalmology</i> , 2016, 10, 1103.	1.8	61
59	Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration. <i>PLoS ONE</i> , 2015, 10, e0129361.	2.5	59
60	Retinal angiomatous proliferation. <i>Survey of Ophthalmology</i> , 2017, 62, 462-492.	4.0	59
61	Diagnosis of retinal health in digital fundus images using continuous wavelet transform (CWT) and entropies. <i>Computers in Biology and Medicine</i> , 2017, 84, 89-97.	7.0	59
62	The complement system and age-related macular degeneration. <i>Eye</i> , 2006, 20, 867-872.	2.1	55
63	Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2019, 137, 626.	2.5	55
64	Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. <i>Eye</i> , 2012, 26, 576-582.	2.1	53
65	Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT) Tj ETQq1 1 0.784314 rgBT /Overlo 3.9 53	3.9	53
66	A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. <i>Acta Diabetologica</i> , 2016, 53, 643-650.	2.5	53
67	Impact on health and provision of healthcare services during the COVID-19 lockdown in India: a multicentre cross-sectional study. <i>BMJ Open</i> , 2021, 11, e043590.	1.9	53
68	Loss of chromatic sensitivity in AMD and diabetes: a comparative study. <i>Ophthalmic and Physiological Optics</i> , 2010, 30, 705-716.	2.0	51
69	Retinal Vascular Calibre, Geometry and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus. <i>Ophthalmologica</i> , 2012, 228, 84-92.	1.9	51
70	Normative spectral domain optical coherence tomography data on macular and retinal nerve fiber layer thickness in Indians. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 316.	1.1	51
71	Ten-year outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration. <i>Eye</i> , 2020, 34, 1888-1896.	2.1	51
72	Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease?. <i>Clinical and Experimental Ophthalmology</i> , 2005, 33, 518-523.	2.6	49

#	ARTICLE	IF	CITATIONS
73	Micropulse diode laser photocoagulation for central serous chorioâ€retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2009, 37, 801-805.	2.6	48
74	Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2011, 95, 386-390.	3.9	48
75	Changing from Snellen to LogMAR: debate or delay?. <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 6-8.	2.6	47
76	Changes in volume of various retinal layers over time in early and intermediate age-related macular degeneration. <i>Eye</i> , 2019, 33, 428-434.	2.1	46
77	Serum Elastin-Derived Peptides in Age-Related Macular Degeneration. , 2005, 46, 3046.		45
78	Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. <i>Eye</i> , 2013, 27, 709-715.	2.1	45
79	Retinal Layer Location of Increased Retinal Thickness in Eyes with Subclinical and Clinical Macular Edema in Diabetes Type 2. <i>Ophthalmic Research</i> , 2015, 54, 112-117.	1.9	45
80	Discrepancy in current central serous chorioretinopathyâ€classification. <i>British Journal of Ophthalmology</i> , 2019, 103, 737-742.	3.9	45
81	Clinical Course and Treatment Outcomes of Sorsby Fundus Dystrophy. <i>American Journal of Ophthalmology</i> , 2008, 146, 228-234.e2.	3.3	44
82	Regression of early diabetic macular oedema is associated with prevention of dark adaptation. <i>Eye</i> , 2011, 25, 1546-1554.	2.1	44
83	Tomographic assessment of therapeutic response to uveitic macular oedema. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 719-723.	2.6	43
84	The Relationship Between Diabetic Retinopathy and Cognitive Impairment. <i>Diabetes Care</i> , 2013, 36, 3177-3186.	8.6	43
85	Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting. <i>American Journal of Ophthalmology</i> , 2017, 174, 160-168.	3.3	43
86	Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. <i>The Cochrane Library</i> , 2012, , CD004239.	2.8	42
87	Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment. <i>Ophthalmology</i> , 2015, 122, 1811-1819.	5.2	41
88	A systematic review of the association of diabetic retinopathy and cognitive impairment in people with Type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 101-110.	2.8	40
89	Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. <i>Eye</i> , 2016, 30, 1063-1071.	2.1	40
90	A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. <i>Ophthalmology</i> , 2020, 127, 377-393.	5.2	40

#	ARTICLE	IF	CITATIONS
91	Ethnic Variation in the Prevalence of Visual Impairment in People Attending Diabetic Retinopathy Screening in the United Kingdom (DRIVE UK). PLoS ONE, 2012, 7, e39608.	2.5	40
92	Choroidal neovascularisation in children. British Journal of Ophthalmology, 2008, 92, 451-454.	3.9	39
93	Non-attendance at diabetic eye screening and risk of sight-threatening diabetic retinopathy: a population-based cohort study. Diabetologia, 2013, 56, 2187-2193.	6.3	39
94	Age-related Macular Degeneration and Modification of Systemic Complement Factor H Production Through Liver Transplantation. Ophthalmology, 2013, 120, 1612-1618.	5.2	39
95	Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye, 2010, 24, 816-824.	2.1	38
96	Predictive Value of Spectral-Domain Optical Coherence Tomography Features in Assessment of Visual Prognosis in Eyes With Neovascular Age-Related Macular Degeneration Treated With Ranibizumab. American Journal of Ophthalmology, 2013, 155, 720-726.e1.	3.3	38
97	Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy. Journal of Diabetes Research, 2015, 2015, 1-9.	2.3	38
98	Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study. American Journal of Ophthalmology, 2018, 190, 1-8.	3.3	38
99	Drusen and pachydrusen: the definition, pathogenesis, and clinical significance. Eye, 2021, 35, 121-133.	2.1	38
100	PREVALENCE OF THE COMPLEMENT FACTOR H AND GSTM1 GENES POLYMORPHISMS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2016, 36, 402-407.	1.7	37
101	Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. Ophthalmology and Therapy, 2018, 7, 361-368.	2.3	37
102	The unmet need for better risk stratification of nonproliferative diabetic retinopathy. Diabetic Medicine, 2019, 36, 424-433.	2.3	36
103	Detection of Diabetic Retinopathy from Ultra-Widefield Scanning Laser Ophthalmoscope Images: A Multicenter Deep Learning Analysis. Ophthalmology Retina, 2021, 5, 1097-1106.	2.4	36
104	Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities. Eye, 2021, 35, 2685-2698.	2.1	35
105	Aging retinal function is improved by near infrared light (670nm) that is associated with corrected mitochondrial decline. Neurobiology of Aging, 2017, 52, 66-70.	3.1	34
106	Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion. American Journal of Ophthalmology, 2017, 182, 118-125.	3.3	34
107	Optically Improved Mitochondrial Function Redeems Aged Human Visual Decline. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, e49-e52.	3.6	34
108	Diabetic macular ischaemia- a new therapeutic target?. Progress in Retinal and Eye Research, 2022, 89, 101033.	15.5	34

#	ARTICLE	IF	CITATIONS
109	Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1). <i>Eye</i> , 2014, 28, 318-326.	2.1	33
110	Adaptive optics: principles and applications in ophthalmology. <i>Eye</i> , 2021, 35, 244-264.	2.1	33
111	A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). <i>Eye</i> , 2015, 29, 1603-1612.	2.1	32
112	Diabetic retinopathy screening guidelines in India: All India Ophthalmological Society diabetic retinopathy task force and Vitreoretinal Society of India Consensus Statement. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 678.	1.1	31
113	POSTERIOR HYALOID CHANGES FOLLOWING INTRAVITREAL TRIAMCINOLONE AND MACULAR LASER FOR DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2008, 28, 1435-1442.	1.7	30
114	Objective Evaluation of Proliferative Diabetic Retinopathy Using OCT. <i>Ophthalmology Retina</i> , 2020, 4, 164-174.	2.4	30
115	Current treatment options for retinal angiomatous proliferans (RAP). <i>British Journal of Ophthalmology</i> , 2010, 94, 672-677.	3.9	29
116	Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy. , 2018, 59, 4277.		29
117	Associations with Corneal Hysteresis in a Population Cohort. <i>Ophthalmology</i> , 2019, 126, 1500-1510.	5.2	29
118	Complement factor H regulates retinal development and its absence may establish a footprint for age related macular degeneration. <i>Scientific Reports</i> , 2019, 9, 1082.	3.3	29
119	Retinal vein occlusion (RVO) guideline: executive summary. <i>Eye</i> , 2022, 36, 909-912.	2.1	29
120	Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 1247-1256.	1.9	28
121	Factors Affecting Reading Speed in Patients with Diabetic Macular Edema Treated with Laser Photocoagulation. <i>PLoS ONE</i> , 2014, 9, e105696.	2.5	28
122	Double-layer sign on spectral domain optical coherence tomography in pachychoroid spectrum disease. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 1796.	1.1	28
123	An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. <i>Eye</i> , 2022, 36, 1154-1167.	2.1	28
124	Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2008, 92, 795-799.	3.9	27
125	Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema. <i>Expert Review of Medical Devices</i> , 2012, 9, 189-197.	2.8	27
126	A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. <i>Clinical Ophthalmology</i> , 2016, 10, 87.	1.8	27

#	ARTICLE	IF	CITATIONS
127	Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. <i>Eye</i> , 2008, 22, 855-859.	2.1	27
128	Validation of Concentric Rings Method as a Topographic Measure of Retinal Nonperfusion in Ultra-Widefield Fluorescein Angiography. <i>American Journal of Ophthalmology</i> , 2015, 160, 1217-1225.e2.	3.3	25
129	Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2018, 96, e835-e839.	1.1	25
130	Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 382-391.	11.4	25
131	Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. <i>Eye</i> , 2010, 24, 203-213.	2.1	23
132	Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. <i>Clinical and Experimental Ophthalmology</i> , 2011, 39, no-no.	2.6	23
133	Changes in Detection of Retinopathy in Type 2 Diabetes in the First 4 Years of a Population-Based Diabetic Eye Screening Program. <i>Diabetes Care</i> , 2013, 36, 2663-2669.	8.6	23
134	Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. <i>BMJ Open</i> , 2015, 5, e008405.	1.9	23
135	Intravitreal aflibercept for diabetic macular oedema: Moorfieldsâ€™ real-world 12-month visual acuity and anatomical outcomes. <i>European Journal of Ophthalmology</i> , 2020, 30, 557-562.	1.3	23
136	Correlation between markers of renal function and sight-threatening diabetic retinopathy in type 2 diabetes: a longitudinal study in an Indian clinic population. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001325.	2.8	23
137	Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). <i>Eye</i> , 2013, 27, 959-963.	2.1	22
138	Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2. , 2015, 56, 5698.		22
139	Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. <i>Eye</i> , 2015, 29, S1-S11.	2.1	22
140	Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept. <i>Ophthalmology</i> , 2016, 123, 1762-1770.	5.2	22
141	Spare the rods and spoil the retina: revisited. <i>Eye</i> , 2016, 30, 189-192.	2.1	22
142	Identification of time point to best define â€˜sub-optimal responseâ€™ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data. <i>Eye</i> , 2017, 31, 1594-1599.	2.1	22
143	Prevalence of diabetic retinopathy and visual impairment in patients with diabetes mellitus in Zambia through the implementation of a mobile diabetic retinopathy screening project in the Copperbelt province: a cross-sectional study. <i>Eye</i> , 2018, 32, 1201-1208.	2.1	22
144	Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 122.	1.6	22

#	ARTICLE	IF	CITATIONS
145	Living with Geographic Atrophy: An Ethnographic Study. <i>Ophthalmology and Therapy</i> , 2019, 8, 115-124.	2.3	22
146	Anti-vascular endothelial growth factor agents for diabetic maculopathy. <i>British Journal of Ophthalmology</i> , 2010, 94, 821-826.	3.9	21
147	Detection of Early Loss of Color Vision in Age-Related Macular Degeneration “ With Emphasis on Drusen and Reticular Pseudodrusen. , 2017, 58, BIO247.		21
148	Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study. <i>Eye</i> , 2021, 35, 592-600.	2.1	21
149	Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. , 2004, , CD004239.		20
150	A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). <i>British Journal of Ophthalmology</i> , 2016, 100, 802-807.	3.9	20
151	Clinical Phenotypes of Poppers Maculopathy and Their Links to Visual and Anatomic Recovery. <i>Ophthalmology</i> , 2017, 124, 1425-1427.	5.2	19
152	Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept. <i>Ophthalmology Retina</i> , 2019, 3, 567-575.	2.4	19
153	The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study. <i>BMC Ophthalmology</i> , 2008, 8, 15.	1.4	18
154	The ORNATE India Project: United Kingdom“India Research Collaboration to tackle visual impairment due to diabetic retinopathy. <i>Eye</i> , 2020, 34, 1279-1286.	2.1	18
155	Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. <i>Eye</i> , 2023, 37, 6-16.	2.1	18
156	Autofluorescence and high-definition optical coherence tomography of retinal artery occlusions. <i>Clinical Ophthalmology</i> , 2010, 4, 1159.	1.8	17
157	Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4). <i>PLoS ONE</i> , 2013, 8, e72755.	2.5	17
158	A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 458.	1.6	17
159	Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 1957-1966.	1.8	17
160	Myocilin Mutations in Patients With Normal-Tension Glaucoma. <i>JAMA Ophthalmology</i> , 2019, 137, 559.	2.5	17
161	<p>A Review of Advancements and Evidence Gaps in Diabetic Retinopathy Screening Models</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 3285-3296.	1.8	17
162	Predictors of Visual Acuity Outcomes after Anti“Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion. <i>Ophthalmology Retina</i> , 2021, 5, 1115-1124.	2.4	17

#	ARTICLE	IF	CITATIONS
163	Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2021, 128, 1736-1747.	5.2	17
164	Dysregulated Serum Lipid Metabolism Promotes the Occurrence and Development of Diabetic Retinopathy Associated With Upregulated Circulating Levels of VEGF-A, VEGF-D, and PlGF. <i>Frontiers in Medicine</i> , 2021, 8, 779413.	2.6	17
165	Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses – An Updated Review. <i>Asia-Pacific Journal of Ophthalmology</i> , 2022, 11, 247-257.	2.5	17
166	Three-Year Visual Outcome and Injection Frequency of Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2013, 230, 27-33.	1.9	16
167	Differences in the topographic profiles of retinal thickening in eyes with and without serous macular detachment associated with diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2014, 98, 182-187.	3.9	16
168	Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1685-1697.	3.1	16
169	Model for Risk-Based Screening of Diabetic Retinopathy in People With Newly-Diagnosed Type 2 Diabetes Mellitus. , 2017, 58, BIO99.		16
170	Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease. <i>Scientific Reports</i> , 2019, 9, 11386.	3.3	16
171	Associations between Retinal Markers of Microvascular Disease and Cognitive Impairment in Newly Diagnosed Type 2 Diabetes Mellitus: A Case Control Study. <i>PLoS ONE</i> , 2016, 11, e0147160.	2.5	16
172	Blood pressure control in type II diabetics with diabetic retinopathy. <i>Eye</i> , 2007, 21, 708-711.	2.1	15
173	Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab. <i>Eye</i> , 2011, 25, 149-153.	2.1	15
174	A Pilot Study on the Combination Treatment of Reduced-Fluence Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2011, 225, 200-206.	1.9	15
175	SUBCLINICAL MACULAR CHANGES AND DISEASE LATERALITY IN PEDIATRIC COATS DISEASE DETERMINED BY QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. <i>Retina</i> , 2019, 39, 2392-2398.	1.7	15
176	Deep Learning-Based Segmentation and Quantification of Retinal Capillary Non-Perfusion on Ultra-Wide-Field Retinal Fluorescein Angiography. <i>Journal of Clinical Medicine</i> , 2020, 9, 2537.	2.4	15
177	Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration. <i>Eye</i> , 2021, 35, 409-417.	2.1	15
178	Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy. <i>Ophthalmology</i> , 2021, 128, 561-573.	5.2	15
179	Capacity building for universal eye health coverage in South East Asia beyond 2020. <i>Eye</i> , 2020, 34, 1262-1270.	2.1	15
180	Patient and provider perspectives on barriers to screening for diabetic retinopathy: an exploratory study from southern India. <i>BMJ Open</i> , 2020, 10, e037277.	1.9	15

#	ARTICLE	IF	CITATIONS
181	What is new in the management of wet age-related macular degeneration?. British Medical Bulletin, 2013, 105, 201-211.	6.9	14
182	A Pilot Study Evaluating the Effects of 670 nm Photobiomodulation in Healthy Ageing and Age-Related Macular Degeneration. Journal of Clinical Medicine, 2020, 9, 1001.	2.4	14
183	Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study. PLoS ONE, 2015, 10, e0128403.	2.5	14
184	Correlation of Fundus Fluorescein Angiography and Spectral-Domain Optical Coherence Tomography in Identification of Membrane Subtypes in Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2014, 231, 153-159.	1.9	13
185	One-Year Progression of Diabetic Subclinical Macular Edema in Eyes with Mild Nonproliferative Diabetic Retinopathy: Location of the Increase in Retinal Thickness. Ophthalmic Research, 2015, 54, 118-123.	1.9	13
186	Treatment Modalities for Idiopathic Macular Telangiectasia: An Evidence-Based Systematic Review of the Literature. Seminars in Ophthalmology, 2017, 32, 384-394.	1.6	13
187	Quantifying Retinal Area in Ultra-Widefield Imaging Using a 3-Dimensional Printed Eye Model. Ophthalmology Retina, 2018, 2, 65-71.	2.4	13
188	Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. Eye, 2019, 33, 295-303.	2.1	13
189	Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration?. Eye, 2006, 20, 43-45.	2.1	12
190	Qualitative and quantitative OCT response of diffuse diabetic macular oedema to macular laser photocoagulation. Eye, 2011, 25, 901-908.	2.1	12
191	Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting. Patient Preference and Adherence, 2016, 10, 949.	1.8	12
192	Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab. Eye, 2019, 33, 930-937.	2.1	12
193	Looking Ahead: Visual and Anatomical Endpoints in Future Trials of Diabetic Macular Ischemia. Ophthalmologica, 2021, 244, 451-464.	1.9	12
194	Indicators of Visual Prognosis in Diabetic Macular Oedema. Journal of Personalized Medicine, 2021, 11, 449.	2.5	12
195	Diagnostic circulating biomarkers to detect vision-threatening diabetic retinopathy: Potential screening tool of the future?. Acta Ophthalmologica, 2022, 100, .	1.1	12
196	Risk of bias: why measure it, and how?. Eye, 2022, 36, 346-348.	2.1	12
197	Protocol on a multicentre statistical and economic modelling study of risk-based stratified and personalised screening for diabetes and its complications in India (SMART India). BMJ Open, 2020, 10, e039657.	1.9	12
198	Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Survey of Ophthalmology, 2022, 67, 1346-1363.	4.0	12

#	ARTICLE	IF	CITATIONS
199	Second eye of patients with unilateral neovascular age-related macular degeneration: Caucasians vs Chinese. <i>Eye</i> , 2006, 20, 923-926.	2.1	11
200	Pulsatile ocular blood flow in asymmetric age-related macular degeneration. <i>Eye</i> , 2007, 21, 506-511.	2.1	11
201	An exploratory study evaluating the effects of macular carotenoid supplementation in various retinal diseases. <i>Clinical Ophthalmology</i> , 2016, 10, 835.	1.8	11
202	Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration. <i>Eye</i> , 2017, 31, 1613-1620.	2.1	11
203	Changes in macular drusen parameters preceding the development of neovascular age-related macular degeneration. <i>Eye</i> , 2019, 33, 910-916.	2.1	11
204	Aflibercept Reduces Retinal Hemorrhages and Intravitreal Microvascular Abnormalities But Not Venous Beading. <i>Ophthalmology Retina</i> , 2020, 4, 689-694.	2.4	11
205	Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naïve patients in the UK: DRAGO study 12-month outcomes. <i>Eye</i> , 2022, 36, 64-71.	2.1	11
206	Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience. <i>Eye</i> , 2010, 24, 793-798.	2.1	10
207	An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema. <i>Clinical Ophthalmology</i> , 2014, 8, 1565.	1.8	10
208	Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 579-586.	1.8	10
209	Diagnostic algorithm utilising multimodal imaging including optical coherence tomography angiography for the detection of myopic choroidal neovascularisation. <i>Eye</i> , 2019, 33, 1111-1118.	2.1	10
210	Diabetic Retinopathy Environment-Wide Association Study (EWAS) in NHANES 2005-2008. <i>Journal of Clinical Medicine</i> , 2020, 9, 3643.	2.4	10
211	Inter-rater reliability for diagnosis of geographic atrophy using spectral domain OCT in age-related macular degeneration. <i>Eye</i> , 2022, 36, 392-397.	2.1	10
212	Deep learning for gradability classification of handheld, non-mydratic retinal images. <i>Scientific Reports</i> , 2021, 11, 9469.	3.3	10
213	Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	10
214	Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-196.	2.8	10
215	Multimodal Imaging Comparison of Polypoidal Choroidal Vasculopathy Between Asian and Caucasian Populations. <i>American Journal of Ophthalmology</i> , 2022, 234, 108-116.	3.3	10
216	The clinician's guide to interpreting a regression analysis. <i>Eye</i> , 2022, 36, 1715-1717.	2.1	10

#	ARTICLE	IF	CITATIONS
217	Complex interventions to implement a diabetic retinopathy care pathway in the public health system in Kerala: the Nayanamritham study protocol. <i>BMJ Open</i> , 2021, 11, e040577.	1.9	10
218	Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2022, 140, 587.	2.5	10
219	Five-year visual outcome following laser photocoagulation of diabetic macular oedema. <i>Eye</i> , 2011, 25, 850-859.	2.1	9
220	Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration. <i>Eye</i> , 2012, 26, 389-393.	2.1	9
221	Ten-year survival trends of neovascular age-related macular degeneration at first presentation. <i>British Journal of Ophthalmology</i> , 2021, 105, 1688-1695.	3.9	9
222	Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial. <i>Value in Health</i> , 2020, 23, 928-935.	0.3	9
223	COVID19 and ophthalmology: a brief summary of the literature. <i>Eye</i> , 2020, 34, 1200-1202.	2.1	9
224	Ethnic Disparities in the Development of Sight-Threatening Diabetic Retinopathy in a UK Multi-Ethnic Population with Diabetes: An Observational Cohort Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 740.	2.5	9
225	Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT. <i>Efficacy and Mechanism Evaluation</i> , 2018, 5, 1-112.	0.7	9
226	Severity of diabetic retinopathy and its relationship with age at onset of diabetes mellitus in India: A multicentric study. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3255.	1.1	9
227	Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration—the PINNACLE trial protocol. <i>Eye</i> , 2023, 37, 1275-1283.	2.1	9
228	Homonymous hemianopia and exotropia: an important management issue. <i>Eye</i> , 2006, 20, 1402-1404.	2.1	8
229	Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab. <i>Eye</i> , 2011, 25, 1612-1616.	2.1	8
230	Determinants of Fixation in Eyes With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab. <i>American Journal of Ophthalmology</i> , 2012, 153, 490-496.e1.	3.3	8
231	Prediction of regression of retinal neovascularisation after panretinal photocoagulation for proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 1715-1721.	1.9	8
232	Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema. <i>PLoS ONE</i> , 2018, 13, e0199693.	2.5	8
233	Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1934.	2.4	8
234	Long-term follow-up of management of choroidal neovascularisation secondary to angioid streaks with intravitreal anti-vascular endothelial growth factor. <i>Eye</i> , 2021, 35, 853-857.	2.1	8

#	ARTICLE	IF	CITATIONS
235	Impact of treatment of diabetic macular edema on visual impairment in people with diabetes mellitus in India. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 671.	1.1	8
236	Outcomes of neovascular glaucoma in eyes presenting with moderate to good visual potential. <i>International Ophthalmology</i> , 2021, 41, 2359-2368.	1.4	8
237	Associations between attainment of incentivised primary care indicators and incident diabetic retinopathy in England: a population-based historical cohort study. <i>BMC Medicine</i> , 2021, 19, 93.	5.5	8
238	The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy. <i>Eye</i> , 2022, 36, 1086-1093.	2.1	8
239	Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. <i>Human Mutation</i> , 2021, 42, 1139-1152.	2.5	8
240	The Diagnostic Accuracy of Double-Layer Sign in Detection of Macular Neovascularization Secondary to Central Serous Chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2022, 236, 271-280.	3.3	8
241	The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure. <i>Ophthalmology</i> , 2022, 129, 498-508.	5.2	8
242	Evaluating a Deep Learning Diabetic Retinopathy Grading System Developed on Mydriatic Retinal Images When Applied to Non-Mydriatic Community Screening. <i>Journal of Clinical Medicine</i> , 2022, 11, 614.	2.4	8
243	Agreement between Time-Domain and Spectral-Domain Optical Coherence Tomography in the Assessment of Macular Thickness in Patients with Idiopathic Macular Telangiectasia Type 2. <i>Ophthalmologica</i> , 2013, 230, 144-150.	1.9	7
244	Posterior Segment Distortion in Ultra-Widefield Imaging Compared to Conventional Modalities. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016, 47, 644-651.	0.7	7
245	Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vessels in Diabetic retinopathy (EMERALD). <i>BMJ Open</i> , 2019, 9, e027795.	1.9	7
246	Need for Vitreous Surgeries in Proliferative Diabetic Retinopathy in 10-Year Follow-Up: India Retinal Disease Study Group Report No. 2. <i>Ophthalmic Research</i> , 2021, 64, 432-439.	1.9	7
247	Hydroxychloroquine hitting the headlines—retinal considerations. <i>Eye</i> , 2020, 34, 1158-1160.	2.1	7
248	Prevalence and incidence of visual impairment in patients with proliferative diabetic retinopathy in India. <i>Scientific Reports</i> , 2020, 10, 10513.	3.3	7
249	Google trends as a surrogate marker of public awareness of diabetic retinopathy. <i>Eye</i> , 2020, 34, 1010-1012.	2.1	7
250	EARLY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS TO CONFIRM FELLOW EYE CHANGES IN ASYMMETRIC TYPE-2 MACULAR TELANGIECTASIA. <i>Retina</i> , 2021, 41, 471-479.	1.7	7
251	Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3076.	1.1	7
252	Prevalence and risk factors for diabetic retinopathy in prediabetes in Asian Indians. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108131.	2.3	7

#	ARTICLE	IF	CITATIONS
253	Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. <i>Advances in Therapy</i> , 2022, 39, 2701-2716.	2.9	7
254	Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2008, 2, 339.	1.8	6
255	Giant Cell Arteritis Presenting as Choroidal Infarction. <i>Case Reports in Ophthalmological Medicine</i> , 2013, 2013, 1-3.	0.5	6
256	Sensitivity and specificity of time-domain versus spectral-domain optical coherence tomography in diabetic macular edema. <i>Indian Journal of Ophthalmology</i> , 2013, 61, 208.	1.1	6
257	Diabetes Complications at Presentation and One Year by Glycated Haemoglobin at Diagnosis in a Multiethnic and Diverse Socioeconomic Population: Results from the South London Diabetes Study. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-8.	2.3	6
258	Association of Longitudinal Changes in Drusen Characteristics and Retinal Layer Volumes with Subsequent Subtype of Choroidal Neovascularisation. <i>Ophthalmic Research</i> , 2020, 63, 375-382.	1.9	6
259	Watching synchronous mitochondrial respiration in the retina and its instability in a mouse model of macular degeneration. <i>Scientific Reports</i> , 2021, 11, 3274.	3.3	6
260	Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. <i>Pharmacoeconomics</i> , 2021, 39, 913-927.	3.3	6
261	Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2021, 139, 501.	2.5	6
262	Development and validation of resource-driven risk prediction models for incident chronic kidney disease in type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 13654.	3.3	6
263	Identifying Peripheral Neuropathy in Colour Fundus Photographs Based on Deep Learning. <i>Diagnostics</i> , 2021, 11, 1943.	2.6	6
264	Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-VEGF Vascular Endothelial Growth Factor Therapy. <i>JAMA Ophthalmology</i> , 2022, 140, 143.	2.5	6
265	Sensitivity analysis in clinical trials: three criteria for a valid sensitivity analysis. <i>Eye</i> , 2022, 36, 2073-2074.	2.1	6
266	Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK. <i>Clinical Ophthalmology</i> , 2008, 2, 347.	1.8	5
267	Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy. <i>Eye</i> , 2010, 24, 1018-1023.	2.1	5
268	Relevance of Retinal Thickness Changes in the OCT Inner and Outer Rings to Predict Progression to Clinical Macular Edema: An Attempt of Composite Grading of Macular Edema. <i>Ophthalmic Research</i> , 2016, 55, 19-25.	1.9	5
269	Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis. <i>Ophthalmic Research</i> , 2017, 58, 49-55.	1.9	5
270	Recurring themes during cataract assessment and surgery. <i>Eye</i> , 2021, 35, 2482-2498.	2.1	5

#	ARTICLE	IF	CITATIONS
271	Scotopic thresholds on dark-adapted chromatic perimetry in healthy aging and age-related macular degeneration. <i>Scientific Reports</i> , 2021, 11, 10349.	3.3	5
272	Incidence and Risk Factors for Macular Atrophy in Acquired Vitelliform Lesions. <i>Ophthalmology Retina</i> , 2022, 6, 196-204.	2.4	5
273	Treatâ€andâ€extend regimens of antiâ€vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and metaâ€analysis. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	5
274	Near infrared spectroscopy reveals instability in retinal mitochondrial metabolism and haemodynamics with blue light exposure at environmental levels. <i>Journal of Biophotonics</i> , 2022, 15, e2916.	2.3	5
275	Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study. <i>Health Technology Assessment</i> , 2022, 26, 1-142.	2.8	5
276	Prevalence of diabetic retinopathy in urban and rural India: A systematic review and meta-analysis. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 1945.	1.1	5
277	Family Practices' Achievement of Diabetes Quality of Care Targets and Risk of Screen-Detected Diabetic Retinopathy. <i>PLoS ONE</i> , 2010, 5, e10424.	2.5	4
278	Optimisation of an automated drusen-quantifying software for the analysis of drusen distribution in patients with age-related macular degeneration. <i>Eye</i> , 2013, 27, 554-560.	2.1	4
279	Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema. <i>Eye</i> , 2017, 31, 1358-1364.	2.1	4
280	Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes. <i>Eye</i> , 2018, 32, 1523-1529.	2.1	4
281	Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-82.	0.7	4
282	Normative Data on Foveal Avascular Zone Dimensions in Four Macular Vascular Layers. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018, 49, 580-586.	0.7	4
283	Complex interventions to implement a diabetic retinopathy care pathway in the public health system in Kerala: the Nayanamritham study protocol. <i>BMJ Open</i> , 2021, 11, e040577.	1.9	4
284	Assessment of optical coherence tomography angiography and multifocal electroretinography in eyes with and without nonproliferative diabetic retinopathy. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3235.	1.1	4
285	Identification of risk factors for targeted diabetic retinopathy screening to urgently decrease the rate of blindness in people with diabetes in India. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3156.	1.1	4
286	Tele-Ophthalmology Versus Face-to-Face Retinal Consultation for Assessment of Diabetic Retinopathy in Diabetes Care Centers in India: A Multicenter Cross-Sectional Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 556-563.	4.4	4
287	Digital Voice Signature: the future of consent?. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 297-297.	2.6	3
288	Hughes syndrome. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 496-498.	2.6	3

#	ARTICLE	IF	CITATIONS
289	A new phenotype of macular dystrophy associated with a mitochondrial A3243G mutation. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 92-93.	2.6	3
290	Retinal Oximetry Differences Between Optic Disc Collateral Vessels and New Vessels. <i>JAMA Ophthalmology</i> , 2017, 135, 1003.	2.5	3
291	The Relationship Between Retinal Vessel Oxygenation and Spatial Distribution of Retinal Nonperfusion in Retinal Vascular Diseases. , 2019, 60, 2083.		3
292	Evaluating the Performance of the Indian Diabetes Risk Score in Different Ethnic Groups. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 285-300.	4.4	3
293	Exploratory Study on Visual Acuity and Patient-Perceived Visual Function in Patients with Subretinal Drusenoid Deposits. <i>Journal of Clinical Medicine</i> , 2020, 9, 2832.	2.4	3
294	Evaluation of real-world early response of DMO to aflibercept therapy to inform future clinical trial design of novel investigational agents. <i>Scientific Reports</i> , 2020, 10, 16499.	3.3	3
295	Prevalence of polypoidal choroidal vasculopathy in Indian population: Risk factors, clinical and imaging characteristics. <i>PLoS ONE</i> , 2020, 15, e0231901.	2.5	3
296	Low Luminance Visual Acuity and Low Luminance Deficit in Proliferative Diabetic Retinopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 358.	2.4	3
297	Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits—a pilot study. <i>Eye</i> , 2021, , .	2.1	3
298	Associations between attainment of incentivized primary care indicators and incident sight-threatening diabetic retinopathy in England: A population-based historical cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1322-1330.	4.4	3
299	Galectins in the Pathogenesis of Common Retinal Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 687495.	3.5	3
300	Microvascular changes precede visible neurodegeneration in fellow eyes of patients with asymmetric type 2 macular telangiectasia. <i>Eye</i> , 2021, , .	2.1	3
301	Burden of Diabetic Retinopathy amongst People with Diabetes Attending Primary Care in Kerala: Nayanamritham Project. <i>Journal of Clinical Medicine</i> , 2021, 10, 5903.	2.4	3
302	Correlation of Optical Coherence Tomography Angiography Characteristics with Visual Function to Define Vision-Threatening Diabetic Macular Ischemia. <i>Diagnostics</i> , 2022, 12, 1050.	2.6	3
303	The Royal College of Ophthalmologists Commissioning guidelines on age macular degeneration: executive summary. <i>Eye</i> , 2022, 36, 2078-2083.	2.1	3
304	Retinal Biochemistry, Physiology and Cell Biology. <i>Developments in Ophthalmology</i> , 2016, 55, 18-27.	0.1	2
305	Video Angiography of Cilioretinal Artery Infarction in Central Retinal Vein Occlusion. <i>Retina</i> , 2016, 36, e33-e35.	1.7	2
306	Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema. <i>Advances in Therapy</i> , 2016, 33, 597-609.	2.9	2

#	ARTICLE	IF	CITATIONS
307	Reply. American Journal of Ophthalmology, 2016, 161, 220-221.	3.3	2
308	Dietary change for macular health of older people: Eating for Eye Health, a pilot community kitchens intervention. Lancet, The, 2018, 392, S37.	13.7	2
309	Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema. BMJ Open Ophthalmology, 2019, 4, e000226.	1.6	2
310	The Detection and Partial Localisation of Heteroplasmic Mutations in the Mitochondrial Genome of Patients with Diabetic Retinopathy. International Journal of Molecular Sciences, 2019, 20, 6259.	4.1	2
311	Long-term follow-up of a case of posterior microphthalmos (PRSS56) with hyperautofluorescent retinal pigment epithelial deposits. European Journal of Ophthalmology, 2020, , 112067212094975.	1.3	2
312	Eplerenone for chronic central serous chorioretinopathy – Authors' reply. Lancet, The, 2020, 396, 1557-1558.	13.7	2
313	Epidemiology of moderately severe and severe non-proliferative diabetic retinopathy in South West England. Eye, 2021, , .	2.1	2
314	Prefilled Eylea Syringe: our recent experience. Eye, 2021, 35, 2083-2085.	2.1	2
315	Sensitivity and specificity of pseudocolor ultrawide field imaging in comparison to wide field fundus fluorescein angiography in detecting retinal neovascularization in diabetic retinopathy. Eye, 2021, , .	2.1	2
316	Localization of Paracentral Acute Middle Maculopathy Using Optical Coherence Tomography Angiography. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 619-624.	0.7	2
317	Tackling diabetic retinopathy from the grassroots. Indian Journal of Ophthalmology, 2020, 68, 8.	1.1	2
318	In vivo fluorescence molecular imaging of the vascular endothelial growth factor in rats with early diabetic retinopathy. Biomedical Optics Express, 2021, 12, 7185.	2.9	2
319	Barriers in establishing systematic diabetic retinopathy screening through telemedicine in low- and middle-income countries. Indian Journal of Ophthalmology, 2021, 69, 2987.	1.1	2
320	Artificial intelligence-based strategies to identify patient populations and advance analysis in age-related macular degeneration clinical trials. Experimental Eye Research, 2022, 220, 109092.	2.6	2
321	Perspectives from clinical trials: is geographic atrophy one disease?. Eye, 0, , .	2.1	2
322	Living Without a Diagnosis: A Patient's Perspective on Diabetic Macular Ischemia. Ophthalmology and Therapy, 2022, 11, 1617-1628.	2.3	2
323	Why is the moon white?. Clinical and Experimental Ophthalmology, 2005, 33, 571-572.	2.6	1
324	Ocular neovascularization: potential for the angiotensin/Tie-2 pathway. Expert Review of Ophthalmology, 2009, 4, 65-78.	0.6	1

#	ARTICLE	IF	CITATIONS
325	Retinal biochemistry, physiology, and cell biology. , 2010, , 15-22.		1
326	Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases. Clinical Ophthalmology, 2010, 4, 913.	1.8	1
327	Unintentional Retinal Displacement. Ophthalmology, 2011, 118, 603-603.e2.	5.2	1
328	Vision Preference Value Scale and Patient Preferences in Choosing Therapy for Symptomatic Vitreomacular Interface Abnormality. JAMA Ophthalmology, 2018, 136, 658.	2.5	1
329	PIN156 INTRAVITREAL THERAPY WITH RANIBIZUMAB VS AFLIBERCEPT VS BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION: A WITHIN TRIAL COST-UTILITY ANALYSIS. Value in Health, 2019, 22, S664.	0.3	1
330	Differences in macular microvascular changes between eyes with central retinal vein occlusion and proliferative diabetic retinopathy. Eye, 2020, 35, 3170-3172.	2.1	1
331	Editorial on the consensus statement on diabetic retinopathy care pathway. Eye, 2020, 34, 1297-1298.	2.1	1
332	Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. Health Technology Assessment, 2021, 25, 1-104.	2.8	1
333	Is immediate treatment necessary for diabetic macular edema after pars plana vitrectomy for tractional complications of proliferative diabetic retinopathy?. International Ophthalmology, 2021, 41, 3607-3614.	1.4	1
334	Early detection of neovascular age-related macular degeneration: an economic evaluation based on data from the EDNA study. British Journal of Ophthalmology, 2022, 106, 1754-1761.	3.9	1
335	Attendance Rate in Patients with Diabetic Macular Edema Receiving Short Messages. Ophthalmology Retina, 2021, 5, 1054-1056.	2.4	1
336	Segmented Macular Layer Volumes from Spectral Domain Optical Coherence Tomography in 184 Adult Twins: Associations With Age and Heritability. , 2020, 61, 44.		1
337	Inflammatory Vascular Disease. , 2007, , 613-687.		1
338	Bridging the valley of death between research and implementing a systematic diabetic retinopathy screening program in low- and medium-income countries. Indian Journal of Ophthalmology, 2021, 69, 3068.	1.1	1
339	The blue circle and 100 years of insulin discovery. Indian Journal of Ophthalmology, 2021, 69, 2920.	1.1	1
340	The role of photodynamic therapy in ophthalmology. British Journal of Hospital Medicine (London,) Tj ETQq0 0 0 rgBTJ/Overlock 10 Tf 50	0.5	1
341	Retinal non-perfusion in the EDRS seven fields compared with widefield fluorescein angiography: correlation and use of extrapolation factor. Retina, 2022, Publish Ahead of Print, .	1.7	1
342	Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy. Eye, 2022, , .	2.1	1

#	ARTICLE	IF	CITATIONS
343	Correlating the patterns of diabetic macular edema, optical coherence tomography biomarkers and grade of diabetic retinopathy with stage of renal disease. <i>International Ophthalmology</i> , 2022, 42, 3333-3343.	1.4	1
344	The Role of Neuroglobin in Retinal Hemodynamics and Metabolism: A Real-Time Study. <i>Translational Vision Science and Technology</i> , 2022, 11, 2.	2.2	1
345	Photodynamic therapy for age-related macular degeneration. <i>Eye</i> , 2005, 19, 1027-1028.	2.1	0
346	Proportion of treatable subtypes of choroidal neovascular membranes in age-related macular degeneration. <i>International Congress Series</i> , 2005, 1282, 312-316.	0.2	0
347	Techniques that alter the concentration of intravitreal triamcinolone: author's reply. <i>Acta Ophthalmologica</i> , 2007, 85, 234-235.	0.3	0
348	Local and not systemic factor H production dictates risk of age-related macular degeneration in liver transplant recipients. <i>Immunobiology</i> , 2012, 217, 1182-1183.	1.9	0
349	OP90â€¦Non-Attendance at Diabetes Eye Screening and Risk of Sight-Threatening Diabetic Retinopathy: Population-based Cohort Study. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, A42.1-A42.	3.7	0
350	Changes in Detection of Retinopathy in Type 2 Diabetes in the First 4 Years of a Population-Based Diabetic Eye Screening Program: Retrospective Cohort Study. <i>Diabetes Care</i> 2013;36:2663â€“2669. <i>Diabetes Care</i> , 2014, 37, 2063.3-2063.	8.6	0
351	Reliability and Convergent Validity of The Nei Vfq-25 with and Without Near and Distance Activity Appendix Items In Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD). <i>Value in Health</i> , 2016, 19, A572.	0.3	0
352	Reply: â€“Myopic foveoschisis: an ectatic retinopathy, not a schisisâ€™. <i>Eye</i> , 2016, 30, 329-330.	2.1	0
353	Reply. <i>American Journal of Ophthalmology</i> , 2017, 174, 186.	3.3	0
354	Reply. <i>American Journal of Ophthalmology</i> , 2017, 174, 176.	3.3	0
355	Intravitreal aflibercept for proliferative diabetic retinopathy â€“ Authors' reply. <i>Lancet, The</i> , 2017, 390, 2141-2142.	13.7	0
356	The effect of vitreous on proliferative diabetic retinopathy and the response to panretinal photocoagulation. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 423-424.	1.9	0
357	Central Serous Chorioretinopathy. , 2017, , 139-159.		0
358	Welcome message from the new Editor-in-Chief. <i>Eye</i> , 2018, 32, 49-49.	2.1	0
359	PSS5 - VISION-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH INTRAVITREAL AFLIBERCEPT: THE AQUA STUDY. <i>Value in Health</i> , 2018, 21, S422-S423.	0.3	0
360	Advances in the diagnosis of sickle cell retinopathy. <i>Expert Review of Ophthalmology</i> , 2018, 13, 267-272.	0.6	0

#	ARTICLE	IF	CITATIONS
361	The past is the prologue to the future. <i>Eye</i> , 2018, 32, 847-848.	2.1	0
362	Baseline Predictive Factors in Diabetic Macular Edema Treated With Anti-Vascular Endothelial Growth Factor Therapy. <i>JAMA Ophthalmology</i> , 2019, 137, 390.	2.5	0
363	A hidden footprint: embryological origins of age related macular degeneration. <i>Eye</i> , 2019, 33, 1675-1676.	2.1	0
364	Fundus Fluorescein Angiography. , 2019, , 83-96.		0
365	Anti-Vascular Endothelial Growth Factor Therapy and Cardiovascular Disease Risk. <i>Frontiers in Diabetes</i> , 2019, , 100-105.	0.4	0
366	Integrated People-Centered Eye Care: The Game Changer. , 2021, , 79-90.		0
367	Response to "Comment on "Drusen and pachydrusen: the definition, pathogenesis and clinical significance". <i>Eye</i> , 2021, , .	2.1	0
368	Reply to: "Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy". <i>Eye</i> , 2021, 35, 3448.	2.1	0
369	Durability of anti-vascular endothelial growth factor agents in neovascular age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 540-541.	2.6	0
370	Reply. <i>Ophthalmology</i> , 2021, 128, e46-e47.	5.2	0
371	Outcome following ranibizimab therapy for neovascular age related macular degeneration in patients with poor, intermediate and good vision. <i>Acta Ophthalmologica</i> , 2009, 87, 0-0.	1.1	0
372	Visual function vs quality of life assessment in patients with laser-treated diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2009, 87, 0-0.	1.1	0
373	Intravitreal bevacizumab (AVASTIN®) in the treatment of diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2010, 88, 0-0.	1.1	0
374	Epidemiology and Aetiopathogenesis of Age-Related Macular Degeneration. , 2013, , 41-62.		0
375	Lightmasks that prevent dark adaptation for non-central diabetic macular oedema: the CLEOPATRA RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-78.	0.7	0
376	The ORNATE India project: Building research capacity and capability to tackle the burden of diabetic retinopathy-related blindness in India. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3058.	1.1	0
377	Cataract surgery in patients with age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2021, 56, 347.	0.7	0
378	Adding screening for "end organ damage" to the noncommunicable disease package in primary care. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3064.	1.1	0

#	ARTICLE	IF	CITATIONS
379	The clinician's guide to randomized trials: interpretation. Eye, 2022, , .	2.1	0
380	Guidelines for patient management: considerations before adoption into practice. Eye, 2022, , .	2.1	0